AKT1 and cancer: Dysregulation of H3K4 methylation enhances gene expression to support pro-oncogenic growth and therapeutic resistance, indicating that H3K4 methylation and associated epigenomic regulation may be a critical downstream effector of aberrant PI3K/AKT signaling in breast and other cancers.